Summary by Moomoo AI
Regeneron reported robust Q3 2024 financial results with total revenues increasing 11% to $3.72 billion. Dupixent global net sales surged 23% to $3.82 billion, while U.S. EYLEA franchise sales grew 3% to $1.54 billion. GAAP diluted EPS rose 30% to $11.54, and non-GAAP diluted EPS increased 8% to $12.46.The company achieved significant regulatory milestones, including FDA approval of Dupixent as the first biologic therapy for COPD with an eosinophilic phenotype. Positive results were reported from pivotal trials in chronic spontaneous urticaria and bullous pemphigoid, with regulatory submissions planned. The company's clinical portfolio expanded to approximately 40 product candidates.Regeneron maintained strong financial position with $18.3 billion in cash and marketable securities. The company continued its share repurchase program, with $2.9 billion remaining available. R&D investments increased 18% to support pipeline advancement, particularly in late-stage oncology programs.
